How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,414 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Microcirculation and Bone Metabolism in Patients With Type 2 Diabetes Mellitus and Charcot Foot

the onset of the debilitating diabetic complications. Condition or disease Intervention/treatment Diabetic Angiopathies Bone Diseases, Metabolic Other: Baseline comparison of microcirculation and bone metabolism Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 50 participants Time Perspective: Prospective Official Title: Bone Metabolism and Endothelial Function in Patients With Type 2 Diabetes Mellitus and Charcot Foot - an Observational Comparative (...) for eligibility information Ages Eligible for Study: 40 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Sampling Method: Probability Sample Study Population 40 patients with type 2 diabetes mellitus will be considered eligible for the study. Patients with a previous diagnosis of type 2 diabetes mellitus and newly diagnosed type 2 DM seen at Tameside Hospital will be recruited into the study. In addition, eligible patients will be identified and referred

2015 Clinical Trials

142. Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

provided by (Responsible Party): Kadmon Corporation, LLC Study Details Study Description Go to Brief Summary: This study will compare the safety, tolerability and efficacy of the combination of KD026 and metformin compared to placebo and metformin on improving glycemic control in patients with type 2 diabetes mellitus. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: KD026 Drug: Placebo Drug: Metformin Phase 2 Study Design Go to Layout table for study information Study (...) Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2015 Clinical Trials

143. Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

: September 6, 2018 Sponsor: Novo Nordisk A/S Information provided by (Responsible Party): Novo Nordisk A/S Study Details Study Description Go to Brief Summary: This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus. Condition or disease Intervention/treatment Phase Metabolism and Nutrition Disorder Obesity Drug: semaglutide Drug: liraglutide Drug: placebo Phase 2 Study Design Go to Layout table (...) Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2015 Clinical Trials

144. A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: liraglutide Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 635 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 (...) A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2015 Clinical Trials

145. Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02496000 Recruitment Status : Completed First Posted : July 14, 2015 Results First Posted : February 17, 2017 Last Update

2015 Clinical Trials

146. Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

controlled blood glucose (7.0%≤HbA1c≤10.5% at randomization)despite at least 8 weeks of metformin monotherapy at stable doses(≥1500 mg/day). Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: PEX168(100µg) Drug: PEX168(200µg) Drug: Placebo Drug: Metformin Phase 3 Detailed Description: Subjects will be randomized to receive either PEX168 100μg, 200μg or PEX 168 Dummy Injection as add-on to metformin hydrochloride. The baseline HbA1c level (HbA1c≤8.5% or HbA1c>8.5)is designed (...) prior to screening: Type 1 diabetes mellitus, single gene mutation DM, DM associated with pancreatic injury, or secondary DM, e.g., DM secondary to Cushing syndrome or acromegalia History of hypertension with SBP>160 mmHg and/or DBP>100 mmHg despite glucose-lowering agents at stable dose (for at least 4 weeks) History of acute/chronic pancreatitis, history of symptomatic cholecystopathy, and the risk factors for pancreatitis including pancreatic injury History of myeloid C-cell carcinoma, history

2015 Clinical Trials

147. PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)

single dose of Afrezza inhaled TI in a euglycemic clamp setting. Condition or disease Intervention/treatment Phase Type 1 Diabetes Mellitus Drug: Technosphere Insulin SAR439065 Afrezza® Phase 1 Detailed Description: The maximum study duration per patient is approximately 9 weeks (screening of 3 to 28 Days, treatment period of 2 days [Periods 1 and 2], washout period of 5 to 19 days [between treatment period], and end-of-study visit of 7 to 14 days after study drug administration in Period 2). Study (...) PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM) PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2015 Clinical Trials

148. A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve subjects with type 2 diabetes mellitus inadequately controlled with oral anti diabetics. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: insulin degludec/liraglutide Drug: insulin glargine Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 1012 participants Allocation (...) A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2015 Clinical Trials

149. A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia

recombinant glucagon in type 1 diabetes mellitus (T1DM) patients under induced hypoglycemia. Secondary Objective: To assess the safety and tolerability and pharmacokinetics (PK) of a single SC dose of SAR438544 versus recombinant glucagon in T1DM patients under induced hypoglycemia. Condition or disease Intervention/treatment Phase Type 1 Diabetes Mellitus Drug: SAR438544 Drug: r-glucagon Drug: insulin Phase 1 Detailed Description: The total duration of study per patient is up to 8 weeks with 3 to 28 days (...) A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration

2015 Clinical Trials

150. A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps

) First Posted : December 7, 2015 Last Update Posted : July 13, 2017 Sponsor: Eli Lilly and Company Information provided by (Responsible Party): Eli Lilly and Company Study Details Study Description Go to Brief Summary: This study evaluates a new test formulation of a glucose lowering drug, insulin lispro, delivered by an insulin pump continuously under the skin. The study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes the new test (...) formulation and its effect on blood sugar levels when it is delivered via an insulin pump. Side effects and tolerability will be documented. The study will last about 4 to 11 weeks, including screening, lead-in and follow up. Screening is required within 28 days prior to entering the study. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 1 Drug: Insulin Lispro Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual

2015 Clinical Trials

151. A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.

in Japanese subjects with type 2 diabetes mellitus. Condition or disease Intervention/treatment Phase Diabetes Diabetes Mellitus, Type 2 Drug: insulin degludec/liraglutide Drug: insulin degludec Drug: liraglutide Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 819 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Trial Comparing (...) A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study

2015 Clinical Trials

152. A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Wi

as well as the overall safety and tolerability of sitagliptin in comparison to that of dapagliflozin after 24 weeks of treatment. The primary hypothesis is that the change from baseline in A1C in participants treated with the addition of sitagliptin is non-inferior compared to that in participants treated with the addition of dapagliflozin after 24 weeks of treatment. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Sitagliptin Drug: Dapagliflozin Drug: Metformin Drug (...) A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Wi A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control

2015 Clinical Trials

153. A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

subcutaneous (SC) doses in healthy subjects and in type 1 diabetes mellitus (T1DM) patients. Secondary Objective: To assess the preliminary pharmacodynamics (PD) and pharmacokinetic (PK) parameters of SAR438544 after single ascending SC doses in healthy subjects and in T1DM patients. Condition or disease Intervention/treatment Phase Type 1 Diabetes Mellitus Drug: SAR438544 Drug: placebo Drug: r-glucagon Phase 1 Detailed Description: Healthy subjects: The total duration of study per subject is up to 4.5 (...) A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2015 Clinical Trials

154. Patients With Diabetic Neuropathy Who Receive Physiotherapy Treatment Will Have a Decrease in Diabetic Foot Ulcers

System Diseases Pathologic Processes Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Foot Diseases Neuromuscular Diseases Nervous System Diseases (...) neuropathy. A group of participants will receive a physiotherapy protocol added to their usual medical treatment and the other group will not receive physiotherapy treatment. Condition or disease Intervention/treatment Phase Diabetic Foot Ulcer Diabetic Neuropathy Peripheral Other: Physiotherapy protocol Not Applicable Detailed Description: Neuropathic diabetic patients present alterations in joint mobility, plantar pressures and ankle and foot function, characteristics related to the development

2018 Clinical Trials

155. Management of Diabetic Patients With Neuropathic Osteoarthropathy (Charcot Foot) : Descriptive Study in Diabetic-foot Centers

Cardiovascular Diseases Foot Ulcer Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies (...) , Charcot foot remains a widely unknown diabetes complication. At this day, there is no national guidelines about diagnosis and treatment of this complication, which is known to alter life quality and to increase risk of foot ulceration and mortality in diabetics. Through this descriptive multicentric study, we will investigate the Charcot foot cares in diabetic-foot centers in France and Belgium. Condition or disease Diabetic Foot Neuroarthropathy Charcot Study Design Go to Layout table for study

2018 Clinical Trials

156. Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.

Angiopathies Vascular Diseases Cardiovascular Diseases Foot Ulcer Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies (...) of the main options for the treatment of the diabetic foot ulcers, but it has many side effects. The aim of this study is to evaluate effectiveness and safety of medical treatments, in this population of patients. Condition or disease Intervention/treatment Diabetic Foot Infection Other: safety and effectiveness of the usual treatments of diabetic foot infections Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 150 participants Observational Model

2018 Clinical Trials

157. Hypertension - not diabetic

the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less 5 40–75% Diabetes mellitus DM002 The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less 8 53-93% DM003 The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 140/80 mmHg or less 10 38-78% Mental health MH003 The percentage (...) of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 12 months 4 50–90% Chronic kidney disease (CKD) CKD005 The contractor establishes and maintains a register of patients aged 18 or over with CKD with classification of categories G3a to G5 (previously stage 3 to 5) 6 Smoking SMOK002 The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD

2018 NICE Clinical Knowledge Summaries

158. Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers

Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety (...) and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02361437 Recruitment Status : Terminated (Investigator's hospital sold and study cancelled) First Posted : February 11, 2015 Last Update Posted : December 13, 2017 Sponsor: Primus

2015 Clinical Trials

159. Management of adults with diabetes undergoing surgery

? Inappropriate use of intravenous insulin infusion ? Management errors when converting from the intravenous insulin infusion to usual medication ? Peri-operative infection. The high-risk surgical patient and the impact of diabetes The high-risk surgical population is made up of elderly patients with co-existing medical conditions undergoing complex or major surgery, often as an emergency. The most important co-morbid diseases include ischaemic heart disease, heart failure, respiratory disease, impaired renal (...) function and diabetes mellitus. There is clear evidence that such diseases are strongly associated with poor outcomes after major surgery 7-10 . The primary aim of perioperative management of the surgical patient with diabetes is to decrease morbidity and hopefully reduce the duration of hospital stay. Diabetes related patient factors associated with worse outcomes Poor peri-operative glycaemia control Previous work has suggested that glycaemic control has a significant impact on the risk of post

2016 Association of British Clinical Diabetologists

160. The Management of Diabetic Foot Full Text available with Trip Pro

-brachial index; DFU, diabetic foot ulcer; HBO, hyperbaric oxygen; MRI, magnetic resonance imaging; NPWT, negative pressure wound therapy; PAD, peripheral arterial disease; PTB, probe to bone; TcP o 2 , transcutaneous oxygen pressure; XR, radiography. Hide Pane Expand all Collapse all Article Outline Background Diabetes mellitus continues to grow in global prevalence and to consume an increasing amount of health care resources. One of the key areas of morbidity associated with diabetes is the diabetic (...) areas in the care of DFUs, they do not cover all the aspects of this complex condition. Going forward as future evidence accumulates, we plan to update our recommendations accordingly. Summary of Recommendations 1. Prevention of diabetic foot ulceration Recommendation 1: We recommend that patients with diabetes undergo annual interval foot inspections by physicians (MD, DO, DPM) or advanced practice providers with training in foot care (Grade 1C). Recommendation 2: We recommend that foot examination

2016 Society for Vascular Surgery

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>